Tharimmune公司获得欧洲纳米粒子专利,以加强癌症药物的交付和效力。 Tharimmune secures European patent for nanoparticles enhancing cancer drug delivery and efficacy.

一家生物技术公司Tharimmune获得欧洲专利局颁发的可生物降解纳米粒子专利,这些纳米粒子改进了癌症治疗中治疗抗体和的提供。 Tharimmune, a biotech company, has been granted a patent by the European Patent Office for biodegradable nanoparticles that improve the delivery of therapeutic antibodies and peptides in cancer treatments. 这些纳米粒子通过降低毒性和改善血液循环,可以提高药物的功效。 These nanoparticles can enhance drug efficacy by reducing toxicity and improving circulation in the bloodstream. Thamimune也在寻求美国专利,并探索进一步发展这一技术的伙伴关系。 Tharimmune is also pursuing a U.S. patent and exploring partnerships to further develop the technology.